Second Sight

Vivani Medical Provides Business Update and Reports Third Quarter Financial Results

Retrieved on: 
Tuesday, November 14, 2023

Vivani Medical, Inc. (Nasdaq: VANI ) (“Vivani” or the “Company”), an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implants, today reported financial results for the third quarter of 2023 and provided a business update.

Key Points: 
  • Vivani Medical, Inc. (Nasdaq: VANI ) (“Vivani” or the “Company”), an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implants, today reported financial results for the third quarter of 2023 and provided a business update.
  • In addition, we are announcing parallel plans to pursue the initiation of the FIH study in Australia.
  • Third Quarter ended September 30, 2023, Financial Results
    Cash Balance: As of September 30, 2023, Vivani had cash, cash equivalents and restricted cash totaling $26.2 million compared to $46.4 million as of December 31, 2022.
  • Research and development expense increased by $0.5 million, or 15%, to $4.4 million in the third quarter of 2023 from $3.9 million in the third quarter of 2022.

Vivani Medical to Present at the Boulder Peptide Symposium

Retrieved on: 
Thursday, September 7, 2023

Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative, preclinical-stage biopharmaceutical company that develops novel, long-term drug implants, announced today that it will present at the upcoming Annual Boulder Peptide Symposium at 11:20 am PST at the Napa Valley Marriott Hotel and Spa in Napa, California on September 19, 2023.

Key Points: 
  • Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative, preclinical-stage biopharmaceutical company that develops novel, long-term drug implants, announced today that it will present at the upcoming Annual Boulder Peptide Symposium at 11:20 am PST at the Napa Valley Marriott Hotel and Spa in Napa, California on September 19, 2023.
  • Medication non-adherence occurs when patients do not take their medication as prescribed.
  • The company has developed, manufactured, and marketed an implantable visual prosthetic device, Argus II®, that delivered meaningful visual perception to blind individuals.
  • Vivani continues to assess strategic options for advancing Cortigent’s pioneering technology.

Vivani Medical Reports First Quarter Financial Results and Provides Business Update

Retrieved on: 
Monday, May 15, 2023

Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants, including lead product NPM-119 for the treatment of patients with type 2 diabetes and/or obesity, today reported financial results for the first quarter and provided a business update.

Key Points: 
  • Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants, including lead product NPM-119 for the treatment of patients with type 2 diabetes and/or obesity, today reported financial results for the first quarter and provided a business update.
  • By mid-2023, we plan to file an IND with the U.S. Food and Drug Administration (the “FDA”) and, if clearance is obtained, initiate LIBERATE-1.
  • In addition, we are seeking to complete the Initial Public Offering for our Cortigent business in the third quarter of 2023 enabling us to continue advancing our neuromodulation technology.
  • The inclusion of Second Sight costs for the first quarter of 2023 totaled $1.7 million.

IntegriChain and Second Sight Solutions to Team up on 340B Issue Prevention for Pharma Manufacturers

Retrieved on: 
Tuesday, April 18, 2023

"340B contract pharmacy arrangements have grown at an annual rate exceeding 25% over the past five years," said Second Sight Director Andrew Brownlee.

Key Points: 
  • "340B contract pharmacy arrangements have grown at an annual rate exceeding 25% over the past five years," said Second Sight Director Andrew Brownlee.
  • We believe this initiative with IntegriChain will help serve the industry by streamlining the removal of ineligible rebates identified by the 340B ESP platform."
  • We are happy to partner with Second Sight on this important work for the Pharma industry."
  • As the first phase of this initiative, IntegriChain and Second Sight will plan to roll out the ICyte Script Management-340 ESP integration to participating pharmaceutical manufacturers in the third quarter of 2023.

Vivani Medical Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Retrieved on: 
Friday, March 31, 2023

Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants, including lead product candidate NPM-119 for the treatment of patients with type 2 diabetes, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update.

Key Points: 
  • Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants, including lead product candidate NPM-119 for the treatment of patients with type 2 diabetes, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update.
  • In August 2022, the business combination of Second Sight and NPM was completed, and the combined company was renamed Vivani.
  • In November 2022, Vivani’s neuromodulation business was established as a wholly-owned subsidiary named Cortigent, Inc., a Delaware corporation.
  • Net Loss: The net loss was $13.9 million in 2022, as compared to $12.8 million in 2021.

USI Expands Cyber Answerlytics Solution Platform

Retrieved on: 
Thursday, September 29, 2022

VALHALLA, N.Y., Sept. 29, 2022 (GLOBE NEWSWIRE) -- USI Insurance Services (USI), a world leader in risk management, employee benefit and retirement consulting, today announced the expansion of its proprietary cyber Answerlytics solution platform to include a total of 14 industry-leading cyber risk management providers focused on helping clients proactively reduce their exposure to financial risk from urgent cyber vulnerabilities and emergent threats.

Key Points: 
  • VALHALLA, N.Y., Sept. 29, 2022 (GLOBE NEWSWIRE) -- USI Insurance Services (USI), a world leader in risk management, employee benefit and retirement consulting, today announced the expansion of its proprietary cyber Answerlytics solution platform to include a total of 14 industry-leading cyber risk management providers focused on helping clients proactively reduce their exposure to financial risk from urgent cyber vulnerabilities and emergent threats.
  • These providers were selected to help USI clients proactively address critical vulnerabilities and to establish and maintain the proper controls and practices on which cyber underwriters focus.
  • Launched in 2021, Answerlytics is a truly differentiated cyber offering from USI that is benefiting our clients and carrier partners through improved risk evaluation, risk mitigation and risk presentation to carriers, stated Nadia Hoyte, national cyber practice leader for USI.
  • David Hallstrom, national cyber advisor for USI, added: We chose our Answerlytics Curated Providers to help our clients receive optimal cyber insurance terms, streamline the cyber procurement process and improve their cyber risk knowledge, including access to weekly threat updates.

Second Sight Medical Products Announces Successful Completion of its Merger with Nano Precision Medical and its Name Change to Vivani Medical, Inc.

Retrieved on: 
Tuesday, August 30, 2022

In connection with the merger, Second Sight changed its name to Vivani Medical, Inc. (Vivani).

Key Points: 
  • In connection with the merger, Second Sight changed its name to Vivani Medical, Inc. (Vivani).
  • ThinkEquity acted as the financial advisor to Second Sight in connection with the merger.
  • Vivani Medical, Inc., which will soon trade under the Nasdaq ticker VANI, is the combination of Nano Precision Medical, Inc. and Second Sight Medical Products, Inc.
  • Prior to the merger, Nano Precision Medical, Inc. was a privately held biopharmaceutical company developing drug implants which utilize its proprietary NanoPortal drug implant technology.

Second Sight Medical Products, Inc. Announces Shareholder Approval for Proposed Merger with Nano Precision Medical, Inc. and other Results of 2022 Annual Meeting

Retrieved on: 
Friday, July 29, 2022

Scott Dunbar, acting Chief Executive Officer stated, These are exciting times for Second Sight as we welcome the Nano Precision Medical team.

Key Points: 
  • Scott Dunbar, acting Chief Executive Officer stated, These are exciting times for Second Sight as we welcome the Nano Precision Medical team.
  • While a few participants discontinued the study due to medical reasons unrelated to Orion, we are seeing encouraging results in the remaining study subjects.
  • About Second Sight Medical Products, Inc.
    Second Sight Medical Products, Inc. (Nasdaq: EYES) develops implantable visual prostheses that are intended to deliver useful artificial vision to blind individuals.
  • About Nano Precision Medical Products, Inc.
    Nano Precision Medical, Inc. is a privately held biopharmaceutical company developing drug implants by leveraging the companys proprietary NanoPortal drug implant technology.

Second Sight Medical Products Announces Year Four NIH Funding of its Orion Study

Retrieved on: 
Monday, July 18, 2022

The funding supports continuation of this important research and testing of the Orion Visual Cortical Prosthesis.

Key Points: 
  • The funding supports continuation of this important research and testing of the Orion Visual Cortical Prosthesis.
  • Orion is intended to convert images captured by a miniature video camera mounted on glasses into a series of small electrical pulses.
  • An early feasibility study of the Orion is currently underway at the Ronald Reagan UCLA Medical Center in Los Angeles and the Baylor College of Medicine in Houston.
  • About Second Sight Medical Products, Inc.
    Second Sight Medical Products, Inc. (Nasdaq: EYES) develops implantable visual prostheses that are intended to deliver useful artificial vision to blind individuals.

Nano Precision Medical Co-Founder and CEO Discusses Proposed Second Sight Merger in Interview to Air on Bloomberg U.S. on the RedChip Money Report®

Retrieved on: 
Thursday, April 14, 2022

The resulting company will focus on development of innovative drug and device medical implants that treat chronic diseases with high unmet medical need.

Key Points: 
  • The resulting company will focus on development of innovative drug and device medical implants that treat chronic diseases with high unmet medical need.
  • To view the interview segment, please visit: https://youtu.be/QaxKGcSt610
    The RedChip Money Report is produced by RedChip Companies Inc., an international Investor Relations and media firm with 30 years experience focused on Discovering Tomorrows Blue Chips Today.
  • The RedChip Money Report" delivers insightful commentary on small cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies.
  • About Second Sight Medical Products, Inc.
    Second Sight Medical Products, Inc. (Nasdaq: EYES) develops implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals.